CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim
Cancer Research and Treatment. 2020;52(2):374-387.   Published online 2019 August 13    DOI: https://doi.org/10.4143/crt.2019.198

Excel Download

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Cancer Research and Treatment. 2020;52(2):374-387   Crossref logo
Link1 Link2 Link3

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
Drug Design, Development and Therapy. 2015;1729   Crossref logo
Link1

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
Pharmacogenomics and Personalized Medicine. 2014;79   Crossref logo
Link1

A Phase II Trial of Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; Preliminary Results
Clinical Lymphoma Myeloma and Leukemia. 2019;19:S359-S360   Crossref logo
Link1 Link2

Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
British Journal of Haematology. 2013;163(5):681-683   Crossref logo
Link1

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
OncoTargets and Therapy. 2014;1717   Crossref logo
Link1

A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMIDE (LEN) IN RELAPSED AND REFRACTORY (R/R) CUTANEOUS (CTCL) AND PERIPHERAL (PTCL) T-CELL LYMPHOMAS: PRELIMINARY RESULTS OF A PHASE II TRIAL
Hematological Oncology. 2019;37:471-472   Crossref logo
Link1 Link2

A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas
European Journal of Cancer. 2019;119:S28   Crossref logo
Link1 Link2

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Drugs. 2017;77(4):435-445   Crossref logo
Link1 Link2 Link3

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
Medical Council. 2017;(14)88-92   Crossref logo
Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.